Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

@article{Becker2009ClinicalEA,
  title={Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.},
  author={Michael Becker and Harold R. Schumacher and Patricia A Macdonald and Eric Lloyd and Christopher Lademacher},
  journal={The Journal of rheumatology},
  year={2009},
  volume={36 6},
  pages={1273-82}
}
OBJECTIVE To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout. METHODS Subjects (n=1086) in this open-label extension study were assigned to fixed-dose daily urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 mg). ULT reassignment was permitted during months 1 to 6 to achieve serum urate (SUA) concentrations between 3.0 and <6.0 mg/dl. Flares requiring treatment, tophus… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 93 extracted citations

Cost-effectiveness of febuxostat in chronic gout

The European Journal of Health Economics • 2013
View 6 Excerpts
Highly Influenced

Febuxostat for treatment of chronic gout.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…